Demonstrates that ERBB3 blockade increases regorafenib sensitivity after first-line TKI resistance, highlighting a new therapeutic target.
This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after sorafenib or lenvatinib resistance.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: